Amphetamine Drugs Market Outlook:
Amphetamine Drugs Market size was valued at USD 11.8 billion in 2025 and is projected to reach USD 17.9 billion by the end of 2035, rising at a CAGR of 4.8% during the forecast period, 2026-2035. In 2026, the industry size of amphetamine drugs is assessed at USD 12.3 billion.
The global market is growing due to the rise of ADHD cases, increased diagnosis and awareness, and use in adults is also on the rise due to wider use in treating sleep disorders such as narcolepsy, newer drug formulations, and active investments by the pharma sector. There is an opportunity to tap into the growth of amphetamine drugs. As per a report by the CDC, November 2024, an estimated 7 million (11.4%) U.S. children aged 3 to 17 years have ever been diagnosed with ADHD. Typically, amphetamine drugs are dispensed for long periods for both public and private usage. The system works mainly on active pharmaceutical ingredients, which are mostly synthesized from amphetamine salts and then formulated into extended-release forms.
Pharmaceutical companies are investing heavily in extended-release and abuse-deterrent versions to improve efficacy and safety, which is increasing the global amphetamine drug market. Additionally, pricing and reimbursement policies (PPI) are playing a significant role in shaping market dynamics, especially in high-income regions such as the U.S. and Europe. As per a report by NLM in August 2024, specialty drugs now account for about 55% of all U.S. drug spending, double the share of a decade earlier, highlighting the growing economic effect of targeted therapies, such as amphetamines. Such a trend underscores the need for balanced regulation to ensure access, affordability, and innovation.
